Healthcare group Alliance Pharma sees revenues rise steady
Alliance Pharma plc, the Wiltshire-based international healthcare group, delivered revenues of £82.4 million in the first half of the year, nudging up just 1.1 per cent on the same period last year.
This included revenue from its most recent US acquisition (ScarAway™ and the US rights to Kelo-Cote™ which helps prevent, treat and reduce the appearance of hypertrophic and keloid scars). Whilst the first half had a mixed performance with regulatory issues resulting in some manufacturing delays in certain smaller products, revenue growth for the Kelo-Cote franchise and anti dandruff shampoo Nizoral was in line with the Board's expectations, and menopause supplement Amberen revenues returned to growth in Q2 on a like-for-like basis. Importantly in-market demand for Kelo-Cote continues to grow strongly and the Board's expectations for Group operating performance in the full year remains unchanged.
READ MORE: South West of England hailed as ‘hotbed of entrepreneurial activity’
However, there was a mixed performance in other consumer healthcare products with regulatory challenges in some products impacting stock availability during the first half of the year. As a result sales in this sector declined 10 per cent to £17.2 million and total consumer healthcare revenues for the Period were £59.7 million up 3.9 per cent on the prior year. Regulatory issues also impacted some prescription medicines with sales down 5.7 per cent but the company said these regulatory issues have been addressed.
